| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 121.8 | 121.6 | 136.3 |
| Other income | 4.4 | 5.1 | 8.8 |
| Total income | 126.2 | 126.6 | 145.0 |
| Profit before exceptional items & tax | 14.7 | 17.1 | 28.1 |
| Exceptional items | 0.0 | 9.1 | 0.0 |
| Profit before tax | 14.7 | 26.2 | 28.1 |
| Net profit | 9.5 | 18.6 | 21.6 |
| Operating margin | 11.6% | 20.7% | 19.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -56.00% |
|---|---|
| Net profit, quarter on quarter | -48.90% |
| Revenue, year on year | -10.60% |
| Operating profit, year on year | -46.60% |
| Operating profit, quarter on quarter | -14.20% |
BSE results filing, NSE: FERMENTA. Figures extracted from the filing.
Fermenta Biotech Ltd: key numbers
- Share price
- ₹566.00
- Market cap
- ₹1,666 Cr
- Revenue (annual)
- ₹525.4 Cr
- Net profit (annual)
- ₹71.77 Cr
- P/E (TTM)
- 27.5×Sector 47.4×
- Promoter holding
- 64.09%+0.00% QoQ
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fermenta Biotech Ltd
All →Fermenta Biotech Other Announcement
KMP Sumesh Gandhi sold a total of 3,900 equity shares in three separate market transactions on September 7, 8, and 9, 2026.
- Value
- ₹0.20 Cr
Fermenta Biotech Partnership
Fermenta Biotech Limited signed an exclusive licence agreement with VIT Vellore to commercialize Vitamin B12 fortification technology for fermented foods, enhancing its product portfolio.
- From
- Vellore Institute of Technology (VIT), Vellore
Fermenta Biotech Promoter Selling: ₹2.2 Cr
Director Prashant Nagre sold 44,000 shares of Fermenta Biotech Ltd via market sale. The transaction value is Rs.2.20 Crore.
- Value
- ₹2.20 Cr
- Promoter stake change
- -0.15%
Fermenta Biotech Credit Rating
Fermenta Biotech Limited received a credit rating upgrade from CARE Ratings. Long-term bank facilities were raised to 'CARE BBB+; Stable' and short-term to 'CARE A2'.
- Value
- ₹173.0 Cr
Fermenta Biotech Management Change
Fermenta Biotech Limited has re-appointed Ms. Rajeshwari Datla as a Non-Executive Non-Independent Director of the company, effective August 11, 2026.
Fermenta Biotech Annual General Meeting
Fermenta Biotech held its AGM and secured shareholder approval for resolutions including financial statements, dividend declaration, and director appointments. All seven resolutions were passed successfully.